Citation

BibTex format

@article{Abouelhadid:2023:10.1186/s12934-023-02125-y,
author = {Abouelhadid, S and Atkins, ER and Kay, EJ and Passmore, IJ and North, SJ and Lehri, B and Hitchen, P and Bakke, E and Rahman, M and Bossé, JT and Li, Y and Terra, VS and Langford, PR and Dell, A and Wren, BW and Cuccui, J},
doi = {10.1186/s12934-023-02125-y},
journal = {Microbial Cell Factories},
pages = {1--13},
title = {Development of a novel glycoengineering platform for the rapid production of conjugate vaccines},
url = {http://dx.doi.org/10.1186/s12934-023-02125-y},
volume = {22},
year = {2023}
}

RIS format (EndNote, RefMan)

TY  - JOUR
AB - Conjugate vaccines produced either by chemical or biologically conjugation have been demonstrated to be safe and efficacious in protection against several deadly bacterial diseases. However, conjugate vaccine assembly and production have several shortcomings which hinders their wider availability. Here, we developed a tool, Mobile-element Assisted Glycoconjugation by Insertion on Chromosome, MAGIC, a novel biotechnological platform that overcomes the limitations of the current conjugate vaccine design method(s). As a model, we focused our design on a leading bioconjugation method using N-oligosaccharyltransferase (OTase), PglB. The installation of MAGIC led to at least twofold increase in glycoconjugate yield via MAGIC when compared to conventional N-OTase based bioconjugation method(s). Then, we improved MAGIC to (a) allow rapid installation of glycoengineering component(s), (b) omit the usage of antibiotics, (c) reduce the dependence on protein induction agents. Furthermore, we show the modularity of the MAGIC platform in performing glycoengineering in bacterial species that are less genetically tractable than the commonly used Escherichia coli. The MAGIC system promises a rapid, robust and versatile method to develop vaccines against serious bacterial pathogens. We anticipate the utility of the MAGIC platform could enhance vaccines production due to its compatibility with virtually any bioconjugation method, thus expanding vaccine biopreparedness toolbox.
AU - Abouelhadid,S
AU - Atkins,ER
AU - Kay,EJ
AU - Passmore,IJ
AU - North,SJ
AU - Lehri,B
AU - Hitchen,P
AU - Bakke,E
AU - Rahman,M
AU - Bossé,JT
AU - Li,Y
AU - Terra,VS
AU - Langford,PR
AU - Dell,A
AU - Wren,BW
AU - Cuccui,J
DO - 10.1186/s12934-023-02125-y
EP - 13
PY - 2023///
SN - 1475-2859
SP - 1
TI - Development of a novel glycoengineering platform for the rapid production of conjugate vaccines
T2 - Microbial Cell Factories
UR - http://dx.doi.org/10.1186/s12934-023-02125-y
UR - https://www.ncbi.nlm.nih.gov/pubmed/37596672
UR - https://microbialcellfactories.biomedcentral.com/articles/10.1186/s12934-023-02125-y
UR - http://hdl.handle.net/10044/1/106175
VL - 22
ER -